服務熱線:400-8098-313
|
最新推薦
|
Job Description
This position will be responsible for conducting the developability assessment on late stage discovery compounds and participate in a cross-functional team to select molecules that can be successfully developed. Using conventional and high throughput technologies and instrumentation including XRPD, TGA/DSC, DVS, HPLC, UPLC, LC/MS, GC/MS, and NMR to provide preformulation data, with a special emphasis on analytical method development and solid phase characterization. The candidate will work closely with colleagues from Drug Discovery, PCC, Toxicology, and DMPK groups to meet quality, quantity and timelines in all projects. Develop analytical methods and formulations for toxicology and in vivo efficacy models. Support formulation development efforts for first in human “Proof of Concept” studies. Generate scientific documents and write developability reports for PHAD and CHAD .
Keyword: CNIBR
Minimum requirements
A Ph.D. or equivalent in Analytical Chemistry with a minimum of 3+ years industrial experience in early drug development. Expertise in preclinical and clinical drug development. Strong skills in physico-chemical characterization, analytical method development and preformulation study. Experience in the salt selection and polymorph screening process. Hands-on experience in XRPD, TGA/DSC, HPLC, LC-MS and other analytical methodologies. Excellent oral and written English.
企業介紹:
諾華(Novartis AG)是全球醫藥保健行業的領導者。其核心業務涉及專利藥,非專利藥,眼睛護理,消費者保健和動物保健等領域。諾華公司總部設在瑞士巴塞爾,業務遍及全球140多個國家和地區。 諾華(中國)生物醫學研究有限公司是諾華全球研發組織――諾華生物醫學研究所(NIBR)的第八個研究基地。我們位于中國上海市張江高科技園區,將成為諾華在亞洲的主要研究中心,以及除在歐美的研究中心外的最主要的研究中心。我們的研究和探索開發活動的重點是發現并開發創新療法,用于治療在亞洲遠未達到醫藥需求的疾病。我們與從不同之處在于將專注現代藥物的發現和開發方法的研究。最初階段,研發工作將專注在引起中國地方性癌癥的感染原因。我們還將開展臨床試驗,進行安全性研究,生物標志物和檢測分析,表達譜、生物分析以及轉化醫學的研究。 |
查看更多 友情鏈接 |
迪醫獵頭 迪醫獵頭網 醫藥獵頭 醫藥獵頭公司 北京醫藥獵頭公司 上海醫藥獵頭公司 廣東醫藥獵頭公司
|